|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:Myonexus_Therapeutics
|
|
gptkbp:CEO
|
gptkb:Doug_Ingram
|
|
gptkbp:clinicalTrials
|
gptkb:SRP-9008
gptkb:SRP-9005
gptkb:Duchenne_muscular_dystrophy
gptkb:SRP-9020
gptkb:SRP-9016
gptkb:SRP-9019
gptkb:SRP-9010
ongoing
gene therapy
muscular dystrophy
Phase 3
SRP-9004
SRP-9006
SRP-9015
SRP-9017
SRP-9001
SRP-9003
SRP-9007
SRP-9009
SRP-9011
SRP-9013
SRP-9014
SRP-9018
SRP-9012
|
|
gptkbp:collaborations
|
gptkb:Stanford_University
gptkb:University_of_Pennsylvania
gptkb:Massachusetts_General_Hospital
gptkb:National_Institutes_of_Health
gptkb:University_of_Florida
gptkb:Children's_Hospital_of_Philadelphia
gptkb:Boston_Children's_Hospital
Pediatric_Research_in_Office_Settings
|
|
gptkbp:employeeCount
|
over 300
|
|
gptkbp:facilities
|
gptkb:Cambridge,_Massachusetts
gptkb:Durham,_North_Carolina
|
|
gptkbp:focus
|
genetic medicine
|
|
gptkbp:founded
|
1980
|
|
gptkbp:founder
|
gptkb:Chris_Garabedian
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sarepta Therapeutics
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:investmentFocus
|
venture capital
|
|
gptkbp:notableEvent
|
gptkb:Viltolarsen
gptkb:Eteplirsen
gptkb:Golodirsen
SRP-9001
|
|
gptkbp:partnerships
|
gptkb:Duke_University
gptkb:University_of_California,_San_Diego
|
|
gptkbp:patentType
|
gptkb:Viltolarsen
gptkb:Eteplirsen
gptkb:Golodirsen
|
|
gptkbp:products
|
therapeutics
|
|
gptkbp:region
|
Worldwide
|
|
gptkbp:research_focus
|
gptkb:Duchenne_muscular_dystrophy
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:tributaryOf
|
gene therapies
|
|
gptkbp:type
|
public company
|
|
gptkbp:website
|
www.sareptatherapeutics.com
|